Literature DB >> 8537651

Quantitative determination of antibodies to type III group B streptococcal polysaccharide.

H K Guttormsen1, C J Baker, M S Edwards, L C Paoletti, D L Kasper.   

Abstract

The susceptibility of neonates to invasive infection with type III group B streptococci (GBS) in a radioactive antigen-binding assay (RABA) has been correlated with low maternal serum levels of capsular polysaccharide-specific antibodies. An ELISA was developed using capsular polysaccharide covalently coupled to human serum albumin. In sera from 35 healthy women, the range of IgG antibodies to GBS III polysaccharide was 0.05-33.0 micrograms/mL, and specific IgA antibodies were 0.08-1.1 micrograms/mL; however, no GBS III capsular polysaccharide-specific antibodies of the IgM isotype were detected by the ELISA. The levels of naturally acquired and vaccine-induced antibodies obtained with this ELISA correlated well with the results of the RABA (Spearman's rank correlation coefficient, .92). The ELISA has two major advantages over the RABA: It measures specific isotypes and subclasses of antibodies, and it can detect type III polysaccharide-specific antibodies at lower concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537651     DOI: 10.1093/infdis/173.1.142

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Measurement of human antibodies to type III group B Streptococcus.

Authors:  D L Kasper; M R Wessels; H K Guttormsen; L C Paoletti; M S Edwards; C J Baker
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

3.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci.

Authors:  E A Albanyan; M S Edwards
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.

Authors:  Francis Michon; Catherine Uitz; Arun Sarkar; Anello J D'Ambra; Maryline Laude-Sharp; Samuel Moore; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2006-08

6.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model.

Authors:  H K Guttormsen; L M Wetzler; R W Finberg; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

8.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.

Authors:  Sharon L Hillier; Patricia Ferrieri; Morven S Edwards; Marian Ewell; Daron Ferris; Paul Fine; Vincent Carey; Leslie Meyn; Dakota Hoagland; Dennis L Kasper; Lawrence C Paoletti; Heather Hill; Carol J Baker
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

10.  Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.

Authors:  Pia S Pannaraj; Morven S Edwards; Kristen T Ewing; Amanda L Lewis; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.